KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018).

Ari Gnanasakthy, Jon Russo, Kajan Gnanasakthy, Nimanee Harris, Colleen Castro

Contemp Clin Trials 120 106860

PMID35901962
PMCID-
DOI10.1016/j.cct.2022.106860
发表日期2022-07-28
摘要

摘要

The Food and Drug Administration (FDA) encourages the assessment of patient-reported outcomes (PROs) in oncology clinical trials. A 2015 review showed that approximately 26% of industry-sponsored oncology trials included assessment of PROs. However, the proportion of recent trials that supported new oncology drug approvals and assessed PROs is unknown. This review found that assessment of PROs was included in about 75% of registration trials that supported 55 new FDA drug approvals during 2014-2018. Patient-reported outcome assessment was included more in randomized controlled trials than in open-label trials (88% vs. 69%, respectively) and more in phase 3 than in phase 2 trials (89% vs. 66%, respectively).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。